Biotech | Pharma | Type/Product | Amount | Terms/Details | |
Company** | Company | Area | (Month) | ||
(Country) | (Symbol/ | ||||
Country) | |||||
Acacia Bio- | Bristol-Myers | Compound profiling | ND | Bristol-Myers licensed technology | |
sciences Inc.* | Squibb Co. | agreement; use of | and will make upfront payment | ||
(NYSE:BMY) | Acacia's Genome | for technology evaluation on a | |||
Reporter Matrix to | limited number of potential thera- | ||||
profile small mole- | peutic compounds; further details | ||||
cules against multiple | ND (4/98) | ||||
disease pathways | |||||
(identifies changes in | |||||
gene expression in | |||||
presence of drug) | |||||
Affymetrix Inc. | Roche Molecular | Joint development of | ND | Affymetrix will manufacture | |
Systems Inc. (mem- | diagnostic tests that | GeneChip probe arrays for both | |||
ber of the Roche | combine Affymetrix's | R & D and commercial phases of | |||
Group; Switzerland) | GeneChip DNA probe | collaboration; Roche Molecular | |||
array technology with | responsible for worldwide clinical | ||||
Roche's PCR gene | development, regulatory approvals | ||||
amplification technol- | and marketing; Roche Molecular | ||||
ogy; initial focus will | will develop instrumentation to | ||||
be diagnostic kits for | support higher throughput use of | ||||
testing HIV drug | GeneChip products; Affymetrix | ||||
resistance as well as | will sell GeneChip arrays to Roche | ||||
p53 gene assays for | Molecular; companies will share | ||||
cancer staging | equally a defined percentage of | ||||
sales (4/98) | |||||
Amrad Corp. | SmithKline | Agreement to develop | ND | SmithKline has option to license | |
(ASX:AML; | Beecham plc | Amrad's vaccine for | vaccine pending successful com- | ||
Australia) | (NYSE:SBH; U.K.) | rotavirus infection | pletion of current clinical trial; | ||
(causes acute gastro- | if it exercises option, SmithKline | ||||
enteritis in children) | will take over further product | ||||
development and commercialize it | |||||
worldwide; Amrad gets milestones | |||||
and royalties (4/98) | |||||
Aradigm Corp. | Novo Nordisk A/S | Agreement to jointly | $50M | Novo Nordisk gets option to | |
(NYSE:NVO; | develop pulmonary | (2.6% | develop technology for delivery | ||
Denmark) | delivery system for | equity) | of compounds in 2 other thera- | ||
insulin (based on | peutic areas outside diabetes; | ||||
Aradigm's AERx | Aradigm got $4M upfront in cash; | ||||
system) and to eval- | Novo bought 0.3M newly issued | ||||
uate its use in deliv- | shares for $5M (25% premium to | ||||
ering other compounds | market) and will buy another $5M | ||||
for regulating blood | in equity in future; Aradigm could | ||||
glucose levels in | get $36M in milestones; Novo will | ||||
diabetes | fund all development costs and | ||||
both companies will fund final | |||||
development of AERx diabetes | |||||
system; Novo has exclusive world- | |||||
wide marketing rights; Aradigm | |||||
will initially manufacture products | |||||
and gets a share of profits (6/98) | |||||
Axys Pharma- | Roche Bioscience | Functional genomics | ND | Roche Bioscience will provide set | |
ceuticals Inc. | (division of Roche | alliance; use of nema- | of genes to which Axys will apply | ||
Holding Ltd.; | tode Caenorhabditis | its functional genomics platform; | |||
Switzerland) | elegans as animal | Axys gets upfront fee and R & D | |||
model system to eval- | funds; Roche Bioscience has | ||||
uate function of genes | option to license discovered targets | ||||
that may serve as drug | for further development of diag- | ||||
targets for therapies | nostic and antisense products; if | ||||
for pain and other | it exercises option, Axys gets | ||||
peripheral nervous | license fees, milestones and royal- | ||||
system disorders | ties; Axys retains rights to develop | ||||
gene therapy and therapeutic pro- | |||||
tein products acting on targets; | |||||
agreement for 15 months, but | |||||
expandable to 24 months (6/98) | |||||
BioChem Pharma | SmithKline | Heads of agreement | ND | Final agreement should be signed | |
Inc. (Canada) | Beecham Biologi- | to develop BioChem | by 3Q:98; BioChem Pharma will | ||
cals SA (Belgium; | Pharma's influenza | get upfront and milestone pay- | |||
unit of SmithKline | vaccines (cell-culture- | ments starting 2Q:98; BioChem | |||
Beecham plc; | derived injectable and | retains exclusive rights in Canada; | |||
NYSE:SBH; U.K.) | nasal formulations and | SmithKline gets exclusive rights | |||
egg-derived nasal formu- | in Europe and rest of world, where | ||||
lation) (injectable cell- | it will manufacture and market | ||||
derived vaccine now | products and share profits; comp- | ||||
completing Phase II/III | anies will form joint venture in | ||||
Canadian trials; nasal | U.S. to which all rights will be | ||||
cell-derived vaccine in | transferred; SmithKline will mar- | ||||
Phase I trials) | ket in U.S. and companies will | ||||
share profits (6/98) | |||||
Caliper Tech- | Hewlett-Packard | Agreement to jointly | $100M | Companies together will invest | |
nologies Corp.* | Co. (NYSE:HWP) | develop 1st-generation | $20M over next year to develop | ||
lab-on-a-chip technol- | miniaturized instruments and then | ||||
ogy (uses liquid inte- | $80M over following 4 years to | ||||
grated circuitry to create | further develop and commercial- | ||||
chemical processing | ize technology; Hewlett-Packard | ||||
systems on a micro- | will develop instrumentation; | ||||
chip) | Caliper will design, develop and | ||||
manufacture chip (5/98) | |||||
ChemTrak Inc. | Pfizer Inc. | Contract research; | $2.4M | Pfizer will pay $0.4M quarterly | |
(NYSE:PFE) | ChemTrak will develop | over next 18 months for test devel- | |||
disposable, quantitative | opment; ChemTrak will be exclu- | ||||
fingerstick whole blood | sive manufacturer of test (which | ||||
test for one of Pfizer's | uses its AccuMeter technology) | ||||
drugs in development | (6/98) | ||||
Connetics Corp. | Suntory Pharma- | Development, supply | $14M | Suntory will pay $1.6M license | |
ceuticals (division | and commercialization | fee and $12.4M in development | |||
of Suntory Ltd.; | agreement on ConXn | milestones (including in U.S.); | |||
Japan) | (recombinant human | Suntory responsible for all dev- | |||
relaxin-H2) for treating | elopment and commercialization | ||||
scleroderma | expenses in Japan; Connetics gets | ||||
royalties; Suntory will buy ConXn | |||||
materials from Connetics; Con- | |||||
nectics retains rights to all other | |||||
indications in Japan and all ex- | |||||
Japan rights on product (4/98) | |||||
Gene Logic Inc. | SmithKline | Bioinformatics collaboration; | ND | SmithKline licensed OPM system | |
Beecham plc | licensing of Gene Logic's | and software tools; Gene Logic | |||
(NYSE:SBH; U.K.) | Object Protocol Model | retains right to license software | |||
(OPM)-based bioinformatics | and products developed under | ||||
system to develop series | collaboration to 3rd parties; Gene | ||||
of customized data bases for | Logic gets licensing fees and | ||||
integrating public and | funding; financial terms ND (5/98) | ||||
proprietary genomic and | |||||
biological data sources into | |||||
SmithKline's data mining | |||||
process | |||||
Gensia Sicor Inc. | Asta Medica AG | Joint development | ND | Companies will co-promote pro- | |
(Germany) | of depot formulations | duct in North America; further | |||
of undisclosed peptides | details ND (5/98) | ||||
as cancer therapies | |||||
(long-acting drug | |||||
delivery) | |||||
GenVec Inc. | Asahi Chemical | Licensing agreement | ND | GenVec licensed U.S. rights to | |
(IPO pending) | Industry Co. Ltd. | on all gene therapy | gene; further details ND (4/98) | ||
(Japan) | applications of tumor | ||||
necrosis factor alpha | |||||
gene (to be developed | |||||
for use in combination | |||||
with radiation therapy) | |||||
Fuso Pharma- | Collaboration to devel- | ND | GenVec gets R & D funding for | ||
ceutical Industries | op gene therapies for | (includes | 5 years as well as milestones; Fuso | ||
Ltd. (Japan) | cancer | equity) | bought undisclosed equity stake in | ||
GenVec on signing; Fuso gets | |||||
rights in Japan with option for | |||||
Korea and Taiwan; GenVec gets | |||||
royalties; GenVec retains right to | |||||
develop and commercialize pro- | |||||
ducts in rest of world (4/98) | |||||
Varian Biosynergy | Joint development of | ND | Companies will collaborate in both | ||
(subsidiary of Var- | cancer therapies by | pre-clinical and clinical develop- | |||
ian Associates Inc.) | combining targeted | ment; Varian will develop equip- | |||
radiation therapy with | ment and software for delivery of | ||||
GenVec's gene therapy | targeted radiation therapy; com- | ||||
(in vivo production of | panies each retain rights to their | ||||
therapeutic products by | respective products and technol- | ||||
gene transfer following | gies (4/98) | ||||
exposure to radiation) | |||||
ImmuLogic | Sankyo Co. Ltd. | License agreement on | ND | ImmuLogic gets license fee, mile- | |
Pharmaceutical | (Japan) | certain of ImmuLogic's | stones and royalties; further | ||
Corp. | patents for recombinant | details ND (5/98) | |||
proteins and peptides; | |||||
for use in treating allergy | |||||
to Japanese cedar pollen | |||||
Immunomedics | Beckman Coulter | Letter of intent to form new | ND | Beckman Coulter will provide its | |
Inc. | Inc. (NYSE:BEC) | company, IBC Pharma- | affinity enhancement technology to | ||
ceuticals, to develop cancer | new company and will join with | ||||
drugs via affinity-enhance- | Immunomedics to raise private | ||||
ment technology (use of bi- | capital to fund the venture; both | ||||
specific humanized mono- | 'parent' companies will share | ||||
clonal antibodies to deliver | patents and technologies; IBC | ||||
therapeutic radionuclides to | Pharmaceuticals will develop affinity- | ||||
cancer cells) | enhancement technology (4/98) | ||||
Incyte Pharma- | Bayer Corp. | Genomic data base | ND | Bayer's global pharmaceutical div ision | |
ceuticals Inc. | (unit of Bayer AG; | agreement for access to Incyte's | will use software for data management | ||
Germany) | LifeTools bio-informatics | and to support research; Incyte will | |||
software and LifeSeq PD | provide consultation services; Incyte | ||||
(annotated version of public | gets subscription fees; further | ||||
cDNA data base) | details ND (4/98) | ||||
Incyte Pharma- | Monsanto Co. | Large-scale, genome- | ND | 3-year agreement (this is 2nd | |
ceuticals Inc. | (NYSE:MTC) | wide application of | agreement between companies); | ||
Incyte's gene expression | Monsanto gets access to up to | ||||
microarray technology | 50,000 DNA microarrays for use | ||||
for functional genomics | across its life sciences programs; | ||||
applications in plant, | Incyte will provide data from | ||||
animal and human | custom and prefabricated DNA | ||||
genomes | microarrays, software to manage | ||||
and analyze data and consulting | |||||
services; other terms ND (5/98) | |||||
IntraBiotics Inc.* | Biosearch Italia | Licensing and supply | ND | IntraBiotics will conduct U.S. | |
SpA (Italy) | agreement for Ramo- | Phase II clinical trials; IntraBiot- | |||
planin (antibacterial | ics gets commercialization rights | ||||
agent for treating multi- | in U.S. and Canada; Biosearch | ||||
drug-resistant bacteria, | gets licensing fee, milestones, | ||||
especially Staphylococ- | royalties and bulk supply pay- | ||||
cus aureus and Entero- | ments; Biosearch will manufacture | ||||
coccus faecalis) | drug substance; IntraBiotics will | ||||
formulate and package it (5/98) | |||||
Irori Inc.* | Bristol-Myers | Combinatorial chemistry | $14.5M | Companies will co-develop the | |
Squibb Co. | collaboration; dev elopment | (equity; | NanoReactor in this 2-year colla- | ||
(NYSE:BMY) | of ultra-high throughput | % ND) | boration; Bristol-Myers will buy | ||
combinatorial chemistry | $4.5M equity stake in Irori and pay | ||||
system using Irori's Nano- | milestones and licensing fees of | ||||
Reactor technology | $10M; additional details ND (6/98) | ||||
(miniaturized micro-reactors | |||||
for screening very large | |||||
numbers of single compounds) | |||||
Isis Pharma- | Merck & Co. Inc. | Research collaboration | $50M | 3-year collaboration; companies | |
ceuticals Inc. | (NYSE:MRK) | on small molecule drugs | will jointly design and synthesize | ||
for treating hepatitis C | small molecule compounds, which | ||||
virus (HCV) infection | Merck will screen in its enzymatic | ||||
assays for HCV replication inhib- | |||||
itors; Isis gets annual research | |||||
funding, one-time technology | |||||
access fee, milestones and royal- | |||||
ties; Merck has commercial rights; | |||||
Isis retains right to use technology | |||||
developed in collaboration in its | |||||
antisense program (6/98) | |||||
Martek Bio- | SmithKline | Research collaboration; | ND | SmithKline Beecham licensed | |
sciences Corp. | Beecham plc | use of Martek's recon- | technology; further details ND | ||
(NYSE:SBH; U.K.) | naissance probe technol- | (5/98) | |||
ogy (employs nuclear | |||||
magnetic resonance spec- | |||||
troscopy) to map bind- | |||||
ing sites where drugs | |||||
interact with receptors | |||||
Medarex Inc. | Bristol-Myers | Research collaboration; | $20M | Bristol-Myers has option to | |
Squibb Co. | use of Medarex's | commercialize antibodies; Meda- | |||
(NYSE:BMY) | HuMAb-Mouse tech- | rex gets $20M in R & D funds, | |||
nology to make high- | license fees and milestones; it also | ||||
affinity fully human | gets royalties (6/98) | ||||
monoclonal antibodies | |||||
to multiple antigens for | |||||
use in Bristol-Myers' | |||||
oncology drug discovery | |||||
programs | |||||
Metra Biosystems | Beckman Coulter | Cross-licensing agree- | ND | Beckman Coulter gets rights to | |
Inc. | Inc. (NYSE:BEC) | ment on patent owned | Metra's Pyrilinks-D (Dpd) test | ||
by Beckman Coulter | (urine-base assay for osteoporosis) | ||||
for use on its automated immuno- | |||||
assay analyzer; Metra gets rights to | |||||
continue to make, use and sell the | |||||
Alkphase-B formation marker (for | |||||
osteoporosis) that it currently | |||||
markets worldwide (5/98) | |||||
Molecular | American Home | DNA microarray tech- | ND | American Home will provide | |
Dynamics Inc. | Products Corp. | nology access agreement; | funding and technical expertise; | ||
and Amersham | (NYSE:AHP) | collaboration for contin- | it gains early access to integrated | ||
Pharmacia | ued development of new | microarray systems, related sup- | |||
Biotech (Sweden) | microarray technologies | port and training programs; micro- | |||
array technology will be accessed | |||||
by multiple research centers with- | |||||
in American Home, including Gen- | |||||
etics Institute, Wyeth-Ayerst and | |||||
American Cyanamid (4/98) | |||||
Bristol-Myers | DNA microarray tech- | ND | Bristol-Myers Squibb will provide | ||
Squibb Co. | nology access agreement; | funding and technical expertise; | |||
(NYSE:BMY) | collaboration for contin- | it gains early access to integrated | |||
ued development of new | microarray systems, related sup- | ||||
microarray technologies | port and training programs (4/98) | ||||
Hoechst-Ariad | DNA microarray tech- | ND | Genomics Center will provide | ||
Genomics Center | nology access agreement; | funding and technical expertise; | |||
(joint venture | collaboration for contin- | it gains early access to integrated | |||
between Ariad | ued development of new | microarray systems, related sup- | |||
Pharmaceuticals | microarray technologies | port and training programs (5/98) | |||
Inc. and Hoechst | |||||
Marion Roussel Inc.) | |||||
Molecular Simu- | Glaxo Wellcome | Glaxo joined Molecular | ND | Scientists at Glaxo's research sites | |
lations Inc. (wholly | plc (NYSE:GLX; | Simulation's pharma- | in U.S. and U.K. will participate | ||
owned subsidiary | U.K.) | ceutical development | in consortium; further details ND | ||
of Pharmacopeia | consortium (involves | (5/98) | |||
Inc.) | application of compu- | ||||
tational chemistry to | |||||
pharmaceutical develop- | |||||
ment and formulation) | |||||
NaviCyte Inc.* | Parke-Davis (div- | R & D collaboration; | ND | Parke-Davis is 3rd member of | |
ision of Warner- | development of Navi- | NaviCyte's IDEA consortium | |||
Lambert Co.; | Cyte's computational | (in vitro determination for evalu- | |||
NYSE:WLA) | pharmacokinetics techn- | ation of absorption simulation | |||
nology (Pk-Informatics) | software system); Parke-Davis will | ||||
to identify drug | make initial and milestone pay- | ||||
development candidates | ments to help develop technology; | ||||
(enables prediction of | Parke-Davis gets license to soft- | ||||
pharmacokinetic | ware and computational models for | ||||
outcomes in humans) | use with its compound libraries; | ||||
it will also fund NaviCyte's eval- | |||||
uation of certain compounds in its | |||||
in vitro experimental systems | |||||
(4/98) | |||||
Neurobiological | Merz + Co. GmbH | Research and marketing | $2.1M | Children's Medical will terminate | |
Technologies Inc. | & Co. (Germany) | alliance with Merz and | its existing license to Neurobiolog- | ||
(OTC Bulletin | and Children's | revenue-sharing partner- | ical Technologies on Memantine | ||
Board: NTII) | Medical Center | ship with Children's | and grant exclusive rights to Merz | ||
Corp. | Medical on orally active | instead; in exchange, Neurobiolo- | |||
neuroprotective drug | gical gets upfront payment of | ||||
Memantine (NMDA | $2.1M from Merz; Neurobiologi- | ||||
receptor antagonist) for | cal and Merz will work together to | ||||
treating neuropathic | select global marketing partner; | ||||
pain, AIDS-related | companies and Children's Medical | ||||
and other dementias | will share clinical data; Neurobio- | ||||
and Alzheimer's | logical and Children's Medical | ||||
disease | will share in revenues from pro- | ||||
duct sales for all indications (4/98) | |||||
NeXstar Pharma- | Glaxo Wellcome | Two-part collaboration: | $10M | Glaxo gets non-exclusive rights to | |
ceuticals Inc. | plc (NYSE:GLX; | use of NeXstar's Selex | (3.5% | use NeXstar's Selex process for | |
U.K.) | drug discovery process | equity) | target validation; NeXstar gets | ||
(combinatorial chemistry | exclusive rights to develop a lipo- | ||||
technology that identifies | somal formulation of Lurtotecan | ||||
specific inhibitors of | for treating cancer; Glaxo invested | ||||
targets, called aptamers) | $10M in NeXstar stock (0.96M | ||||
for target validation in | shares at $10.39 each for a 3.5% | ||||
Glaxo's functional | stake); Glaxo also gets certain | ||||
genomics program; dev- | rights to develop aptamers as | ||||
elopment of liposomal | therapeutics, on which NeXstar | ||||
formulation of Glaxo's | gets milestones and royalties; | ||||
cancer drug candidate | NeXstar gets license to Lurtotecan | ||||
Lurtotecan (topoisomerase | and Glaxo gets milestones and | ||||
I inhibitor) | royalties on marketed products; | ||||
Glaxo has option to participate in | |||||
development of this product in | |||||
exchange for licensing fees and | |||||
shared development costs (5/98) | |||||
Oncogene Science | Fujirebio Inc. | Collaboration to format | ND | 4-year agreement; Fujirebio gets | |
Diagnostics Inc. | (Japan) | cancer diagnostic tests | non-exclusive license to develop, | ||
(wholly owned sub- | on Fujirebio's automated | manufacture and sell several | |||
sidiary of OSI | clinical instrument | cancer assays in Japan; Oncogene | |||
Pharmaceuticals Inc.) | LumiPulse | gets licensing fees, R & D funds | |||
and royalties (5/98) | |||||
Oncormed Inc. | Merck & Co. Inc. | Oncormed will provide ras | ND | Oncormed will analyze patient samples | |
(NYSE:MRK) | gene testing services for Merck's | (gene characterization and pharma- | |||
Phase I clinical trials of an anti- | cogenomics); further details ND (5/98) | ||||
cancer therapeutic | |||||
Orchid Bio- | Dynal AS | License agreement on Dynal's | ND | Orchid gets exclusive license to | |
computer Inc.* | (Norway) | magnetizable bead technologies | (includes | Dynal's bead technologies; Dynal | |
for use in Orchid's micro- | equity) | made undisclosed equity invest ment | |||
chemical processing chips | in Orchid; further details ND (4/98) | ||||
Oxford Glyco- | Pfizer Inc. | Collaborative research | $50M | 2-year research program and | |
Sciences plc (U.K.) | (NYSE:PFE) | agreement to apply | (1.5% | 5-year clinical collaboration; | |
Oxford's proteomics | equity) | Pfizer bought 0.54M shares for | |||
technology to identify | $2.5M in a private placement con- | ||||
disease-specific proteins | current with Oxford's 4/98 IPO | ||||
as diagnostics, clinical | (same price per share); Pfizer will | ||||
markers of disease and | fund research for 2 years; Oxford | ||||
drug development targets; | also gets milestones and royalties; | ||||
1st focus is Alzheimer's | total value of deal up to $50M; | ||||
disease | companies will jointly own intel- | ||||
lectual property; Oxford has exclu- | |||||
sive rights to commercialize diag- | |||||
nostic markers; once analysis of | |||||
Pfizer's Alzheimer's samples is | |||||
complete, it has option to select a | |||||
2nd disease indication (4/98) | |||||
Oxford Molecular | The Procter & | Use of Oxford Molecular's- | ND | ND (5/98) | |
Group plc (U.K.) | Gamble Co. | RS3 Discovery and RS3 | |||
(NYSE:PG) | Discovery High Throughput | ||||
Screening research | |||||
information management | |||||
software in Procter & | |||||
Gamble's discovery | |||||
research programs | |||||
Peptide Therapeu- | Pasteur Merieux- | Collaborative agree- | ND | Pasteur Merieux-OraVax gets | |
tics Group plc | OraVax (joint ven- | ment to develop vac- | worldwide exclusive option to use | ||
(U.K.) | ture between Ora- | cines for treating | Peptide Therapeutics' vaccine de- | ||
Vax Inc. and | Helicobacter pylori | livery technology; if it exercises | |||
Pasteur Merieux | infection by incorpor- | option, Peptide Therapeutics gets | |||
Connaught [unit | ating Pasteur Merieux- | license fees, upfront and milestone | |||
of Rhone-Poulenc | OraVax's H. pylori | payments as well as royalties; Pep- | |||
SA; France]) | antigens into Peptide | tide Therapeutics retains rights to | |||
Therapeutics' Salmo- | license delivery system to other | ||||
nella typhi -based oral | parties for use in other vaccines | ||||
vaccine delivery system | (4/98) | ||||
Pharmaceutical | Eli Lilly & Co. | Licensing of certain of Lilly's | ND | Pharmaceutical Product gets | |
Product Develop- | (NYSE:LLY) | genitourinary compounds | worldwide license to compounds; | ||
ment Inc. | to develop as treatments | Lilly gets licensing fees and roy- | |||
for bladder dysfunction and | alties; Lilly gets 1st option to re- | ||||
sexual dysfunction | license compounds in future (5/98) | ||||
Phylos Inc.* | Hoechst Research | Collaboration to jointly | $27M | 5-year collaboration; companies | |
and Technology | develop applications of Phylos' | (equity; | will jointly develop and have co- | ||
Deutschland GmbH | directed protein evolution | % ND) | exclusive rights to technology; | ||
& Co. KG (HR&T; | technology (in vitro formation | HR&T will take undisclosed | |||
wholly owned sub- | of mRNA-protein fusions | equity stake in Phylos; further | |||
sidiary of Hoechst | allows repeated rounds of | details ND (4/98) | |||
AG; Germany) | mutation and selection | ||||
of peptides or proteins) | |||||
QLT PhotoThera- | C.R. Bard Inc. | Alliance to combine QLT's | ND | Bard will fund product develop- | |
peutics Inc. | photodynamic therapy with | ment and clinical research; Bard | |||
(Canada) | Bard's catheter-based intra- | gets exclusive worldwide market- | |||
vascular delivery systems as | ing rights; QLT gets royalties; QLT | ||||
therapy for reducing arterial | retains option to co-fund R & D | ||||
restenosis (localized drug | at later date in exchange for | ||||
delivery) | increased share of revenues (4/98) | ||||
Ribozyme Pharma- | Roche Bioscience | Functional genomics | ND | Roche Bioscience will provide | |
ceuticals Inc. | (division of Roche | collaboration; use of | in vivo models for undisclosed | ||
Holding Ltd.; | combinatorial ribozyme | disease pathways; Roche Bio- | |||
Switzerland) | library to identify genetic | science will conduct clinical dev- | |||
therapeutic targets | elopment and commercialization; | ||||
(identifies genes by | Ribozyme will design, synthesize | ||||
phenotype without prior | and deliver ribozymes; Roche Bio- | ||||
knowledge of sequence) | science has rights to small mole- | ||||
cule and ribozyme-based thera- | |||||
peutics against validated targets; | |||||
Ribozyme has certain limited | |||||
rights to ribozyme-based thera- | |||||
peutics; Roche will fund R & D, | |||||
pay milestones and royalties (5/98) | |||||
Seattle Genetics | Bristol-Myers | Licensing of Bristol- | ND | Seattle Genetics was founded by | |
Inc.* | Squibb Co. | Myer's monoclonal | 2 former Bristol-Myers scientists; | ||
(NYSE:BMY) | antibody-based cancer | Seattle Genetics licensed the entire | |||
targeting program | program and paid Bristol-Myers a | ||||
(includes immunotoxins, | one-time licensing fee; Bristol- | ||||
antibody-based drug | Myers gets royalties; other details | ||||
conjugates, others) | ND (4/98) | ||||
Sheffield Pharma- | Zambon Group | Strategic alliance to | $25M | Zambon made $2.15M equity | |
ceuticals Inc. | SpA (Italy) | develop 4 drugs for | (13% equity) | investment in Sheffield (including | |
treating respiratory | the $0.65M it paid as an option fee | ||||
disease using Shef- | in 4/98); Sheffield gets $2M interest- | ||||
field's Metered Solu- | free loan as advance on future mile- | ||||
tion Inhaler (MSI) | stones; Zambon will assume all | ||||
(drugs include albuterol, | development costs (estimated at | ||||
beclomethasone, ipra- | $20M) for 4 drugs; Sheffield gets | ||||
tropium and cromolyn) | milestones on NDA approval of each | ||||
of 4 drugs and for 1st European | |||||
product licenses for each drug; | |||||
Sheffield gets royalties on Zambon's | |||||
sales and copromotion rights in U.S.; | |||||
Sheffield retains rights to non-respi- | |||||
ratory disease applications of MSI | |||||
system (option agreement 4/98; | |||||
final agreement 6/98) | |||||
Soane BioSciences | The Perkin-Elmer | Collaboration to develop auto- | ND | Perkin-Elmer made undisclosed | |
Inc.* | Corp. (NYSE:PKN) | mated and integrated genetic | (includes | equity investment in Soane; both | |
analysis systems based on | equity) | companies will invest in joint research | |||
Soane's microfluidics technology | and product development; Perkin- | ||||
(electric fields move reagents | Elmer gets exclusive worldwide | ||||
through microcapillaries on | license to commercialize products; | ||||
chips) | Soane will manufacture and supply | ||||
the microfluidic chips (5/98) | |||||
Sparta Pharma- | Schering-Plough | Licensing agreement on Sparta's | ND | Schering-Plough paid Sparta up- | |
ceuticals Inc. | Corp. (NYSE:SGP) | Spartaject drug delivery system | front license fee; Sparta also gets | ||
(for injection of poorly water | milestones and royalties (4/98) | ||||
soluble or insoluble compounds) | |||||
for use with Schering's oral anti- | |||||
cancer agent Temodal (in develop- | |||||
ment for treating recurrent | |||||
malignant melanoma) | |||||
Structural Bio- | Yamanouchi | Drug discovery collaboration on | ND | ND (4/98) | |
informatics Inc.* | Pharmaceutical | undisclosed target of | |||
Co. Ltd. (Japan) | Yamanouchi's; use of Structural | ||||
Bioinformatics' computational | |||||
molecular modeling and virtual | |||||
screening technology to identify | |||||
small molecule drug candidates | |||||
Therapeutic Anti- | G.D. Searle & Co. | Research collaboration; | $8M | Therapeutic Antibodies will devel- | |
bodies Inc. | (division of Mon- | development of ovine | op, manufacture and register pro- | ||
santo Co.; NYSE: | polyclonal antibody to | duct; Searle will pay $8M to fund | |||
MTC) | undisclosed therapeutic | R & D and buy product supplies | |||
target of Searle's | ($1M paid on signing); Searle gets | ||||
worldwide marketing rights; com- | |||||
panies will share revenues (5/98) | |||||
TheraTech Inc. | Astra AB | Use of TheraTech's oral trans- | ND | Astra will market product world- | |
(Sweden) | mucosal delivery technology | wide; TheraTech gets R & D pay- | |||
to develop undisclosed peptide | ments, licensing fees and royalties | ||||
as treatment for pain (peptide | (5/98) | ||||
being developed by Astra and | |||||
BioChem Pharma Inc.) | |||||
Trega Biosciences | Novartis Pharma | Research collaboration | $39M | Trega will screen its combinator- | |
Inc. | AG (Switzerland) | and license agreement | ial chemistry libraries and confirm | ||
on orally active small | activity and function for drug can- | ||||
molecules for treating | didates; companies will collabor- | ||||
diseases mediated by | ate to optimize candidates and test | ||||
melanocortin receptor | preclinically; Novartis will conduct | ||||
pathway (associated | clinical development and commer- | ||||
with MC-4 receptor), | cialize products worldwide; Trega | ||||
including Type II | has option to get an equity invest- | ||||
diabetes, obesity and | ment from Novartis; Trega gets | ||||
Syndrome X | payments for past research, current | ||||
R & D funding and milestones | |||||
worth up to $39M for the 1st pro- | |||||
duct (up to $19M in guaranteed | |||||
funding); Trega also gets royalties; | |||||
Trega will get additional mile- | |||||
stones and royalties for subsequent | |||||
products (deal could be worth | |||||
$50M-$75M in all) (5/98) | |||||
Tripos Inc. | Boehringer Ingel- | Software consulting and | ND | Boehringer Ingelheim will use | |
heim R & D (Aus- | custom software devel- | customized software to access bio- | |||
tria; unit of Boeh- | opment agreement; use | logical screening, chemical and | |||
ringer Ingelheim | of Tripos' Web-based | genomic data (3/98) | |||
GmbH; Germany) | scientific information | ||||
services | |||||
NOTES: | |||||
# This chart contains information on new agreements only, covering the time between March 25, 1998 and June 15, 1998. It does not include arrangements that are classified strictly as production, manufacturing, marketing and/or distribution and supply agreements; a chart covering these arrangements will appear in the June 29, 1998, issue of BioWorld Financial Watch. The chart above also does not include any collaborations that involve agricultural product development (which are covered periodically in this publication). | |||||
A chart covering modified agreements and terminated agreements between big pharma and biotech companies for the same time period (March 25, 1998 - June 15, 1998) will also appear in the June 29, 1998 issue of BioWorld Financial Watch. | |||||
ASX = Australia Stock Exchange; ND = Not disclosed, reported and/or available | |||||
* Private companies are indicated with an asterisk. | |||||
** Unless otherwise noted, the trading symbols for public biotechnology companies can be found by referring to the BioWorld Stock Report For Public Biotechnology Companies on pp. 13-14. |
To read more on related topics, click on one of the words below.